Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology G... von STRAUSS, Gary M, HERNDON, James E, VOKES, Everett E, GREEN, Mark R, MADDAUS, Michael A, JOHNSTONE, David W, JOHNSON, Elizabeth A, HARPOLE, David H, GILLENWATER, Heidi H, WATSON, Dorothy M, SUGARBAKER, David J, SCHILSKY, Richard L

Volltext

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer von SOCINSKI, Mark A, NOVELLA, Silvia, TYE, Lesley, SELARU, Paulina, CHAO, Richard C, SCAGLIOTTI, Giorgio V, BRAHMER, Julie R, ROSELL, Rafael, SANCHEZ, Jose M, BELANI, Chandra P, GOVINDAN, Ramaswamy, ATKINS, James N, GILLENWATER, Heidi H, PALLARES, Cinta

Volltext

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL von Siddiqi, Tanya, Soumerai, Jacob D., Dorritie, Kathleen A., Stephens, Deborah M., Riedell, Peter A., Arnason, Jon, Kipps, Thomas J., Gillenwater, Heidi H., Gong, Lucy, Yang, Lin, Ogasawara, Ken, Thorpe, Jerill, Wierda, William G.

Volltext

Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer von Jones, David R., Moskaluk, Christopher A., Gillenwater, Heidi H., Petroni, Gina R., Burks, Sandra G., Philips, Jennifer, Rehm, Patrice K., Olazagasti, Juan, Kozower, Benjamin D., Bao, Yongde

Volltext

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicent... von Dimopoulos, Meletios A, Prof, Moreau, Philippe, Prof, Palumbo, Antonio, Prof, Joshua, Douglas, Prof, Pour, Ludek, Prof, Hájek, Roman, Prof, Facon, Thierry, Prof, Ludwig, Heinz, Prof, Oriol, Albert, Prof, Goldschmidt, Hartmut, Prof, Rosiñol, Laura, Prof, Straub, Jan, Prof, Suvorov, Aleksandr, Prof, Araujo, Carla, Prof, Rimashevskaya, Elena, Prof, Pika, Tomas, Prof, Gaidano, Gianluca, Prof, Weisel, Katja, Prof, Goranova-Marinova, Vesselina, Prof, Schwarer, Anthony, Prof, Minuk, Leonard, Prof, Masszi, Tamás, Prof, Karamanesht, Ievgenii, Prof, Offidani, Massimo, Prof, Hungria, Vania, Prof, Spencer, Andrew, Prof, Orlowski, Robert Z, MD, Gillenwater, Heidi H, MD, Mohamed, Nehal, PhD, Feng, Shibao, PhD, Chng, Wee-Joo, Prof

Volltext

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors von Infante, Jeffrey R., Mendelson, David S., Burris, Howard A., Bendell, Johanna C., Tolcher, Anthony W., Gordon, Michael S., Gillenwater, Heidi H., Arastu-Kapur, Shirin, Wong, Hansen L., Papadopoulos, Kyriakos P.

Volltext

Phase I Trial of Intrapleural Docetaxel Administered Through an Implantable Catheter in Subjects with a Malignant Pleural Effusion von Jones, David R., Taylor, Matthew D., Petroni, Gina R., Shu, Jianfen, Burks, Sandra G., Daniel, Thomas M., Gillenwater, Heidi H.

Volltext

In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone von McCune, Jeannine S., Hawke, Roy L., LeCluyse, Edward L., Gillenwater, Heidi H., Hamilton, Geraldine, Ritchie, James, Lindley, Celeste

Volltext

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer von Hensing, Thomas A, Hanna, Nasser H, Gillenwater, Heidi H, Gabriella Camboni, M, Allievi, Cecilia, Socinski, Mark A

Volltext

Treatment options for small cell lung cancer von Wolf, Todd, Gillenwater, Heidi H

Volltext

Second-line treatment of small-cell lung cancer von MacCallum, Cecilia, Gillenwater, Heidi H

Volltext

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Smal... von Wierda, William G., Dorritie, Kathleen A., Munoz, Javier, Stephens, Deborah M., Solomon, Scott R., Gillenwater, Heidi H., Gong, Lucy, Yang, Lin, Ogasawara, Ken, Thorpe, Jerill, Siddiqi, Tanya

Volltext

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Coho... von Siddiqi, Tanya, Soumerai, Jacob D., Dorritie, Kathleen A., Stephens, Deborah M., Riedell, Peter A., Arnason, Jon E., Kipps, Thomas J., Gillenwater, Heidi H., Gong, Lucy, Yang, Lin, Ogasawara, Ken, Wierda, William G.

Volltext

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with... von Siddiqi, Tanya, Dorritie, Kathleen Anne, Soumerai, Jacob Drobnyk, Stephens, Deborah Marie, Dubovsky, Jason A, Gillenwater, Heidi H., Gong, Lucy, Thorpe, Jerill, Yang, Lin, Wierda, William G.

Volltext

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer von SHORD, Stacy S, FAUCETTE, Stephanie R, GILLENWATER, Heidi H, PESCATORE, Scott L, HAWKE, Roy L, SOCINSKI, Mark A, LINDLEY, Celeste

Volltext

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase... von Siddiqi, Tanya, Soumerai, Jacob D., Wierda, William G., Dubovsky, Jason A., Gillenwater, Heidi H., Gong, Lucy, Mitchell, Alan, Thorpe, Jerill, Yang, Lin, Dorritie, Kathleen A.

Volltext

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Mara... von Siddiqi, Tanya, Soumerai, Jacob D., Dorritie, Kathleen A., Stephens, Deborah M., Riedell, Peter A., Arnason, Jon E., Kipps, Thomas J., Gillenwater, Heidi H., Gong, Lucy, Dubovsky, Jason A., Rytlewski, Julie, Yang, Lin, Wierda, William G.

Volltext

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies von Teoh, Jeffrey, Johnstone, Timothy G., Christin, Brian, Yost, Rachel, Haig, Neil A., Mallaney, Mary, Radhakrishnan, Aditya, Gillenwater, Heidi H., Albertson, Tina, Guptill, Paul, Brown, Lauren F., Ramsborg, Christopher G., Hause, Ronald J., Larson, Ryan P.

Volltext

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing von DONAHUE, Angela, MCCUNE, Jeannine S, FAUCETTE, Stephanie, GILLENWATER, Heidi H, KOWALSKI, Richard J, SOCINSKI, Mark A, LINDLEY, Celeste

Volltext

A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer von Gillenwater, Heidi H., Stinchcombe, Thomas E., Qaqish, Bahjat F., Tyann, Maureen, Hensing, Thomas A., Socinski, Mark A.

Volltext